• Jin Tae Hong
  • Jaesuk Yun
Jin Tae Hong


1988 B.S. College of Pharmacy, Chungbuk National University, Korea  
1990 M.S. College of Pharmacy, Chungbuk National University, Korea  
1996 Ph.D. Graduate Center for Toxicology, Univ. of Kentucky, U.S.A



1990-2001 Senior Researcher, Korea Food and Drug Administration(KFDA), Korea
2002-2005 Adjunct Researcher, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Korea
2002-present Advisory Board Member, (Functional Food, Cosmetic and Drug), Korea Food and Drug Administration (KFDA), Korea
2007-2008 Visiting Scholar, University of Kentucky, U.S.A
2008-present Director, Medical Research Center, Korea
2011-present Director, Bio-Valley for Academy-Industry Convergence in Osong



1995-present Member, Society of Toxicology, U.S.A
1995-present Member, American Association for Cancer Research, U.S.A
2000-present Editoial Board Member, The Korean Society Of Toxicology, The Korean Society of Applied Phamacology, Korea
2008-present Editoial Board Member, Journal of Medicinal Food, Journal of Alzheimer's Disease
2005-present Vice President, The Korean Society of Toxicogenomics and Toxico- proteomics, Korea
2007-present Chief of Research Planing, The Pharmaceutical Society of Korea
2015-present Vice president, The Korean Society of Applied Pharmacology, Korea
2015-present Chief of Academic Committee, The Pharmaceutical Society of Korea


Research Areas

1) Chemoprevention and Mechanisms

2) Alzheimer’s Disease and Anti-AD

3) Genomic and cellular signals

Jaesuk Yun


2008.4.1 – 2012.3.26 Ph.D. Graduate school of Medicine NAGOYA UNIVERSITY, JAPAN
1999.3.2 – 2001.2.24 M.S. College of Pharmacy CHUNGBUK NATIONAL UNIVERSITY, REPUBLIC OF KOREA
1995.3.2 – 1999.2.25 B.S. College of Pharmacy CHUNGBUK NATIONAL UNIVERSITY, REPUBLIC OF KOREA


2017.3.1 -2018.8.31 Professor, Wonkwang University, REPUBLIC OF KOREA
2012.4.1-2012.11.3O POST DOC fellowship, Graduate school of Medicine NAGOYA UNIVERSITY, JAPAN

Research Areas

1) 약물 남용에 의한 의존성 치료 및 예방 연구

2) 정신신경질환과 종양의 통합 치료 타깃 연구


Selected Publications

  • Lee YS, Jung YY, Park MH, Yeo IJ, Im HS, Nam KT, Kim HD, Kang SK, Song JK, Kim YR, Choi DY, Park PH, Han SB, Yun JS, Hong JT. Deficiency of parkin suppresses melanoma tumor development and metastasis through inhibition of MFN2 ubiquitination. Cancer Lett. 2018 Oct 1;433:156-164.
  • Kim KC, Yun J, Son DJ, Kim JY, Jung JK, Choi JS, Kim YR, Song JK, Kim SY, Kang SK, Shin DH, Roh YS, Han SB, Hong JT. Suppression of metastasis through inhibition of chitinase 3-like 1 expression by miR-125a-3p-mediated up-regulation of USF1. Theranostics. 2018 Aug 7;8(16):4409-4428.
  • Kim SY, Lamichhane S, Ju JH, Yun J Protective Effect of Octylmethoxycinnamate against UV-Induced Photoaging in Hairless Mouse via the Regulation of Matrix metalloproteinases. Int J Mol Sci. 2018 Jun 22;19(7).
  • Gu SM, Lee HP, Ham YW, Son DJ, Kim HY, Oh KW, Han SB, Yun J, Hong JT Piperlongumine Improves Lipopolysaccharide-Induced Amyloidogenesis by Suppressing NF-KappaB Pathway. Neuromolecular Med. 2018 Sep;20(3):312-327.
  • Yun J, Yeo IJ, Hwang CJ, Choi DY, Im HS, Kim JY, Choi WR, Jung MH, Han SB, Hong JT. Estrogen deficiency exacerbates Aβ-induced memory impairment through enhancement of neuroinflammation, amyloidogenesis and NF-ĸB activation in ovariectomized mice. Brain Behav Immun. 2018 Oct;73:282-293.
  • Kim S, Choi KH, Yun J. Exploration of alternative test methods to evaluate phototoxicity of ophthalmic agents by using Statens Seruminstitut Rabbit Cornea cell lines and 3D human reconstituted cornea models. PLoS One. 2018 May 21;13(5):e0196735
  • Yun J, Park MH, Son DJ, Nam KT, Moon DB, Ju JH, Hwang OK, Choi JS, Kim TH, Jung YS, Hwang DY, Han SB, Yoon DY, Hong JT IL-32 gamma reduces lung tumor development through upregulation of TIMP-3 overexpression and hypomethylation. Cell Death Dis. 2018 Feb 21;9(3):306
  • Gu SM, Lee HJ, Lee TH, Song YJ, Kim YH, Han KM, Shin J, Park HK, Kim HS, Cha HJ, Yun J. A synthetic cannabinoid JWH-210 reduces lymphoid organ weights and T-cell activator levels in mice via CB2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2017 Dec;390(12):1201-1209
  • Yun J, Lee KW, Eom JH, Kim YH, Shin J, Han K, Park HK, Kim HS, Cha HJ Potential for Dependence on Lisdexamfetamine - In vivo and In vitro Aspects. Biomol Ther (Seoul). 2017 Nov 1;25(6):659-664
  • Han KM, Ahn SY, Seo H, Yun J, Cha HJ, Shin JS, Kim YH, Kim H, Park HK, Lee YM, Bosentan and Rifampin Interactions Modulate Influx Transporter and Cytochrome P450 expression and Activities in Primary Human Hepatocytes. Biomol Ther (Seoul). 2017 Feb 6. doi: 10.4062/biomolther.2016.153.
  • Gu SM, Yun J, Son DJ, Kim HY, Nam KT, Kim HD, Choi MG, Choi JS, Kim YM, Han SB, Hong JT. Piperlongumine attenuates experimental autoimmune encephalomyelitis through inhibition of NF-kappaB activity. Free Radical Biology and Medicine. 2017. 103, 133-145
  • Yun J, Gu SM, Lee TH, Song YJ, Seong S, Kim YH, Cha HJ, Shin J, Oh H, Jung K, Ahn C, Park HK, Kim HS. Synthetic cannabinoid-induced immunosuppression augments cerebellar dysfunction in tetanus-toxin treated mice. Biomolecules & Therapeutics. 2016. Nov 25, i: 10.4062/biomolther.2016.11.6
  • Yun J, Yoon KS, Lee T, Lee H, Gu SM, Song YJ, Cha HJ, Han KM, Seo H, Shin J, Park H, Kim HS, Kim Y. Synthetic cannabinoid, JWH-030, induces QT prolongation through hERG channel inhibition. Toxicol. Res., 2016, 5, 1663-1671 Sep,7
  • Jeon SY, Kim YJ, Kim YH, Shin J, Yun J, Han K, Park HK, Kim HS, Cha HJ. Abuse potential and dopaminergic effect of alkyl nitrites. Neurosci Lett. 2016 Aug 26;629:68-72
  • Cha HJ, Lee KW, Eom JH, Kim YH, Shin J, Yun J, Han K, Kim HS. 5-(2-Aminopropyl)benzofuran and phenazepam demonstrate the possibility of dependence by increasing dopamine levels in the brain. Pharmacol Biochem Behav. 2016 Oct;149:17-22
  • Yun J, Kim SY, Yoon KS, Shin H, Jeong HS, Chung H, Kim YH, Shin J, Cha HJ, Han KM, Hyeon S, Lee TH, Park HK, Kim HS. P21 (Cdc42/Rac)-activated kinase 1 (pak1) is associated with cardiotoxicity induced by antihistamines. Arch Pharm Res. 2016 12. 39(12): 1644-1652.
  • Yun J, Oliynyk S, Lee Y, Kim J, Yun K, Jeon R, Ryu J, Oh S. Ajoene restored behavioral patterns and liver glutathione level in morphine treated C57BL6 mice. Arch Pharm Res. 2017
  • Gu SM, Park MH, Yun HM, Han SB, Oh KW, Son DJ, Yun JS, Hong JT. CCR5 knockout suppresses experimental autoimmune encephalomyelitis in C57BL/6 mice. Oncotarget 2016 Mar 15. 7(13):15382-15393
  • Cha HJ, Kim YJ, Jeon SY, Kim YH, Shin J, Yun J, Han K, Park HK, Kim HS. Neurotoxicity induced by alkyl nitrites: Impairment in learning/memory and motor coordination. Neurosci Lett 2016 Apr 21. 619:79-85
  • Lee YH, Yun JS, Jung JC, Oh S, Jung YS. Anti-tumor activity of benzylideneacetophenone derivatives via proteasomal inhibition in prostate cancer cells. DIE PHARMAZIE 2016 May 1. 71:274-279
  • Hwang CJ, Choi DY, Jung YY, Lee YJ, Yun JS, Oh KW, Han SB, Oh S, Park MH, Hong JT. Inhibition of p38 pathway-dependent MPTP-induced dopaminergic neurodegeneration in estrogen receptor alpha knockout mice. Hormones and Behavior. 80:19-29. 2016 Apr 1.
  • Yun JS, Gu SM, Yun HM, Son DJ, Park MH, Lee MS, Hong JT. Myelin oligodendrocyte glycoprotein (MOG35-55)-induced experimental autoimmune encephalomyelitis is ameliorated in interleukin-32 alpha transgenic mice. Oncotarget. 6(38):40452-63. 2015DEC01.
  • Cha HJ, Seong YH, Song MJ, Jeong HS, Shin J, Yun JS, Han K, Kim YH, Kang H, Kim HS. Neurotoxicity of synthetic cannabinoids JWH-081 and JWH-210. Biomolecules & Therapeutics 23(6), 597-603. 2015 NOV.
  • Furukawa-Hibi Y, Nagai T, Yun JS, Yamada K. Stress increases DNA methylation of the neuronal PAS domain 4 (NPAS4) gene. Neuroreport 26(14), 827-832. 2015 Sep. 30.
  • Yun JS, Chung E, Choi KH, Cho DH, Song YJ, Han KM, Cha HJ, Shin JS, Seong WK, Kim YH, Kim HS. Cardiovascular safety pharmacology of sibutramine. Biomolecules & Therapeutics 23(4), 386-389. 2015 Jul
  • Kim YH, Bae YJ, Kim HS, Cha HJ, Yun JS, Shin JS, Song WK, Lee YM, Han KM. Measurement of human cytochrome P450 enzyme induction based on mesalazine and mosapride citrate treatments using a luminescent assay. Biomolecules & Therapeutics 23(5), 486-492. 2015 sep.
  • Yun JS, Lee Y, Yun K, Oh S. Bergenin decreases the morphine-induced physical dependence via antioxidative activity in mice. Arch. Pharm. Res 38(6), 1248-1254. 2015 Jun.
  • Yun JS, Kim SY. Antihistamines modulate the integrin signaling pathway in H9C2 Rat cardiomyocytes: possible association with cardiotoxicity. Human & Experimental Toxicology 34(8), 796-807, 2015 Aug
  • Yun JS, Hwangbo E, Lee JP, Chon CR, Kim PA, Jeong IH, Park MY, Park RW, Kang SJ, Choi DW. Analysis of an ECG record database reveals QT interval prolongation potential of famotidine in a large Korean population. Cardiovascular Toxicology 15(2): 197-202. 2015 Apr.



  • Therapeutic Agent for Drug Abuse and Addiction Comprising L-THP as Active Ingredient, Patent No. 1010540930000. Jul. 28, 2011
  • Therapeutic Agent for Drug Abuse and Addiction Comprising Baicalein as Active Ingredient, Patent No. 1008043120000. Feb. 11, 2008
  • Therapeutic Agent for Drug Abuse and Addiction Comprising Baicalin as Active ingredient, Patent No. 1008043110000. Feb. 11, 2008
  • Anodynes with Reduced Drug Addiction, Patent No. 1007794190000. Nov. 20, 2007
  • Therapeutic Agent for Drug Abuse and Addiction Comprising Saikosaponin A as Active Ingredient, Patent No. 1007499310000. Aug. 17, 2007
  • Therapeutic Agent for Narcotics Addiction, Patent No. 1007159390000. May. 2, 2007